Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

Company Overview

Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland.

Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections. The company also maintains a development pipeline targeting drug-resistant pathogens and other areas of high unmet medical need.

Basilea supplies its products in multiple international markets through a combination of direct commercial operations and partnerships. Its medicines are marketed across Europe and in other regions, including the United States, depending on the product and applicable regulatory approvals. The company is listed on the SIX Swiss Exchange and its shares also trade in the United States over the counter.

Key Stats

• Today's Range: $77.40 to $77.40
• 50-Day Range: $60.28 to $77.40
• 52-Week Range: $59.29 to $77.40
• Volume: N/A
• Average Volume: 5 shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Basilea Pharmaceutica Stock Analysis - MarketRank™

Basilea Pharmaceutica scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Basilea Pharmaceutica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Basilea Pharmaceutica has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Basilea Pharmaceutica has a P/B Ratio of 6.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.00% of the float of Basilea Pharmaceutica has been sold short.

Short Interest Ratio / Days to Cover

Basilea Pharmaceutica has a short interest ratio ("days to cover") of 7.72.

Change versus previous month

Short interest in Basilea Pharmaceutica has recently increased by 256.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Basilea Pharmaceutica does not currently pay a dividend.

Dividend Growth

Basilea Pharmaceutica does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Basilea Pharmaceutica has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Basilea Pharmaceutica this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Basilea Pharmaceutica insiders have not sold or bought any company stock.

Percentage Held by Institutions

Basilea Pharmaceutica has minimal institutional ownership at this time.

Company Calendar

• Today: 9/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BPMUF
• CIK: N/A
• Web: www.basilea.com
• Phone: (161) 606-1111
• Fax: 41-61-606-1112
• Employees: 189
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 5.11
• Quick Ratio: 4.68

Sales & Book Value

• Annual Sales: $280.43 million
• Price / Sales: 3.63
• Cash Flow: $3.85 per share
• Price / Cash Flow: 20.11
• Book Value: $11.73 per share
• Price / Book: 6.60

Miscellaneous

• Outstanding Shares: 13,170,000
• Free Float: N/A
• Market Cap: $1.02 billion
• Optionable: Not Optionable
• Beta: 0.22